When you're a STAT+ subscriber, you get discounts on our STAT Reports and events, free access to premium data tools like our Obesity Drug Tracker, as well as in-depth daily coverage and analysis of the life sciences.
Date: Tuesday, July 9, 2024 at 11:00 a.m. EDT Location: Virtual
The immune-checkpoint inhibitor market alone was worth $15.5B in 2023. But could new diagnostics help it exceed its $53.5B predicted value in 2025? Here, AI is becoming a powerful tool. So will all drugs soon come with their own AI diagnostics? Who will fund their creation and distribution? And what is the clinical appetite for such tools — and will patients accept them? Join pharmaceutical, clinical, and AI experts to discuss the impact of AI diagnostics on industry and patients.
Date: Wednesday, July 24, 2024 at 1:00 p.m. EDT Location: Virtual
Invasive meningococcal disease (IMD) is rare but devastating. The CDC's Advisory Committee on Immunization Practices (ACIP) is considering changes to the adolescent meningococcal vaccination schedule that could impact immunization policies. STAT Brand Studio discusses these potential revisions with Richard H. Hughes IV, Will Humble, and Leslie Maier, exploring the importance of school vaccination requirements and potential effects of schedule changes on public health and equity.
Date: October 16–17, 2024 Location: 60 State St 33rd floor, Boston, MA + Virtual
It doesn't take a rocket scientist to see that getting new health technologies to market is incredibly hard, with companies in biotech and health tech falling apart as the funding environment worsens. At our flagship summit event, we'll cover everything from drug development and technology invention to dealing with regulators, courting investors, and pricing and selling products.
-jpg.jpeg?width=420&upscale=true&name=Adams-Biotech-Scorecard-Featured-Image-1600x900%20(1)-jpg.jpeg)
No comments